Are the current conservative treatments for Peyronie's disease evidence-based?

BJU International

Volumn 94, Issue 1, 2004, Pages 3-4

  Gontero, Paolo ^a   Frea, Bruno ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZOATE POTASSIUM; ALPHA TOCOPHEROL; ALPHA2B INTERFERON; CALCIUM CHANNEL BLOCKING AGENT; COLCHICINE; TAMOXIFEN; VASOACTIVE AGENT; VERAPAMIL;

CLINICAL FEATURE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DRUG EFFICACY; EVIDENCE BASED MEDICINE; EXTRACORPOREAL LITHOTRIPSY; HUMAN; META ANALYSIS; NOTE; PEYRONIE DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; EVIDENCE-BASED MEDICINE; HUMANS; INJECTIONS, INTRALESIONAL; MALE; PENILE INDURATION;

EID: 3242784049     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04945.x     Document Type: Note

References (14)

1. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990; 144: 1376-81
2. Teloken C, Rhoden EL, Grazziotin TM, Da Ros CT, Sogari PR, Vargas Souto CA. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999; 162: 2003-5
3. Gholami SS, Gonzalez-Cadavid NF, Lin CS, Rajfer J, Lue TF. Peyronie's disease: a review. J Urol 2003; 169: 1234-41
4. Ralph DJ, Minhas S. The management of Peyronie's disease. BJU Int 2004; 93: 208-15
5. Aversa A, Rocchietti-March M, Caprio M, Giannini D, Isidori A, Fabbri A. Anxiety-induced failure in erectile response to intracorporeal prostaglandin-E1 in non-organic male impotence: a new diagnostic approach. Int J Androl 1997; 20: 126-31
6. Hauck EW, Hackstein N, Vosshenrich R. Diagnostic value of magnetic resonance imaging in Peyronie's disease: a comparison both with palpation and ultrasound in the evaluation of plaque formation. Eur Urol 2003; 43: 293-300
7. Mynderse LA, Monga M. Oral therapy for Peyronie's disease. Int J Imp Res 2002; 14: 340-4
8. Carson CC. Potassium para-aminobenzoate for the treatment of Peyronie's disease: is it effective? Tech Urol 1997; 3: 135-9
9. Prietro Castro RM, Leva Vallejo ME, Regueiro JC, Anglada Curado FJ, Alvarez J, Requena Tapia MJ. Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease. BJU Int 2003; 91: 522-4
10. Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol 2002; 168: 621-5
11. Judge JS, Wisniewski ZS. Intralesional interferon in the treatment of Peyronie's disease: a pilot study. Br J Urol 1997; 79: 40-2
12. Brake M, Loertzer R, Horsch R, Keller H. Treatment of Peyronie's disease with local interferon-α2b. BJU Int 2001; 87: 654-7
13. Ahuja S, Bivalacqua TJ, Case J, Vincent M, Sikka SC, Hellstrom WJ. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2b in the treatment of Peyronie's disease. J Androl 1999; 20: 444-8
14. Hauck EW, Mueller UO, Bschleipfer T, Schmelz HU, Diemer T, Weidner W. Extracorporeal shock wave therapy for Peyronie's disease, exploratory meta-analysis of clinical trials. J Urol 2004; 171: 740-5